Biotest AG: Biotest erwirbt Vertriebsgesellschaft in Brasilien
Biotest AG / Key word(s): Acquisition
19.01.2011 / 17:11
Biotest acquires Brazilian distributor
- Acquisition of Biotest distributor 'Marcos Pedrilson Produtos
Hospitalares Ltda.' in Rio de Janeiro
- Immediate sales in 2011
- Strong sales and earnings growth expected in the medium term based on
new market approvals of immunoglobulins
Dreieich, 19 January 2011. Biotest AG, Dreieich, has acquired all interests
in 'Marcos Pedrilson Produtos Hospitalares Ltda'. The company, located in
Rio de Janeiro, was the current distributor of Biotest and holds all plasma
protein registrations of Biotest for the Brazilian market.
The company acquired under a share deal has an office in Rio de Janeiro,
product registrations, a quality control laboratory and a warehouse near
Sao Paulo airport. In 2009/ 2010 Marcos Pedrilson Produtos Hospitalares
Ltda. sold Hepatect(R) CP and Megalotect(R). Hepatect(R) CP is a
hyperimmunoglobulin to prevent Hepatitis B infection following accidental
exposure to Hepatitis B virus and is also used to prevent reinfection after
liver transplantations. Megalotect(R) is an immunoglobulin for prophylaxis
of clinical manifestations of cytomegalovirus infections in patients
subjected to immunosuppressive therapy. In 2011 product sales of
hyperimmunoglobuliins and human albumin are projected.
By acquiring Marcos Pedrilson Produtos Hospitalares Ltda. Biotest will have
it's own subsidiary in the biggest Latin American market. It is planned to
expand the portfolio of the products marketed in Brazil step by step.
'Latin America represents one of the biggest economies of the future. With
the acquisition of 'Marcos Pedrilson Produtos Hospitalares Ltda.' we have
completed another step within our strategic internationalization process of
our plasma protein business' commented Dr. Joachim Herborg, responsible for
International Marketing and Sales of the Biotest Group. 'We have an
immediate share in the growing Brazilian plasma protein market and will be
substantially expanding our capacities and extending our product range'.
Brazil is the fifth biggest country worldwide with respect to area and
inhabitants (approx. 190 Mio.) with a continously growing population. The
plasma derivatives market had a volume of 300 Mio. USD in 2009 (+30% from
2007). In addition, Brazil has a large transplantation market (>1300
liver transplantations in 2009). Due to the relatively high Hepatitis B
incidence rate of 6% Biotest's Hepatitis B portfolio fits well to the high
medical needs in the country.
Brazil has several trade agreements with other Latin American countries and
therefore qualifies as a base for operations to start distribution to other
countries in South America.
For additional information please visit our website www.biotest.de.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for microbiology. With a value added chain that
extends from pre-clinical and clinical development to worldwide sales,
Biotest has specialised primarily in the areas of application of immunology
and haematology. In its Plasma Protein segment, Biotest develops and
markets immunoglobulins, coagulation factors and albumins based on human
blood plasma. These are used for diseases of the immune and haematopoietic
systems. In the Biotherapeutic segment, Biotest researches into the
clinical development of monoclonal antibodies, including in the indications
of rheumatoid arthritis and cancer of plasma cells. The products of the
Microbiological Monitoring segment are primarily used in hygiene
monitoring. Biotest has more than 1,900 employees worldwide. The preference
shares of Biotest AG are listed in the SDAX on the Frankfurt stock
exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
End of Corporate News
---------------------------------------------------------------------
19.01.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
109470 19.01.2011
